Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension

Wb, White; Wj, Elliott; Johnson, MF; Black, H.

doi:10.1038/sj.jhh.1001137

Cited by 15 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…White et al [47] analyzed data from three studies comparing verapamil with placebo in 281 patients with stage I to III hypertension. Throughout the 4-to 8-week study period, verapamil equally affected obese (BMI > 28) and nonobese patients.…”

Section: Response To Antihypertensive Treatmentmentioning

confidence: 99%

Ambulatory blood pressure monitoring in childhood and adult obesity

Ben‐Dov¹,

Bursztyn

2009

Current Science Inc

View full text Add to dashboard Cite

Body mass and body fat are known modulators of blood pressure (BP) measured by clinic sphygmomanometry. However, the ambulatory BP-monitoring characteristics unique to obesity have not been widely studied. We reviewed the literature on ambulatory BP monitoring for links between measures of body adiposity in lean and overweight children and adults and various BP measures obtained by ambulatory monitoring. Collectively, the findings suggest significant associations of adiposity with ambulatory BP and heart rate, sleep-related BP dipping, and the white-coat phenomenon.

show abstract

Section: Response To Antihypertensive Treatmentmentioning

confidence: 99%

Ambulatory blood pressure monitoring in childhood and adult obesity

Ben‐Dov¹,

Bursztyn

2009

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…White et al 18) reported that subjects with BMI 25 kg/m 2 (BMI 25 − 30 kg/m 2 ) were included in non-obese subjects; therefore, we adopted BMI ≥ 30 kg/m 2 as obese men in this study. All subjects were free of the signs, symptoms, and history of any overt chronic disease.…”

Section: Subjectsmentioning

confidence: 99%

Is Pentraxin 3 Involved in Obesity-Induced Decrease in Arterial Distensibility?

Miyaki

Maeda

Yoshizawa

et al. 2010

JAT

View full text Add to dashboard Cite

Aim: Obesity is a strong risk factor for cardiovascular morbidity and mortality. In addition, decreased central arterial distensibility is recognized as an independent risk factor for cardiovascular disease (CVD). Obese subjects exhibit low arterial distensibillity; however, the mechanism responsible for the decrease in arterial distensibility in obese subjects has not yet been elucidated. Pentraxin 3 (PTX3), a recently identified member of the pentraxin family of proteins, is produced in areas of atherosclerosis. A recent study has revealed that the PTX3 level may indicate the vascular inflammatory status. The aim of this study was to investigate plasma PTX3 concentrations and arterial distensibility in obese subjects. ) participated in this study. We measured arterial compliance (using simultaneous B-mode ultrasound and arterial applanation tonometry of the common carotid artery); -stiffness index, an index of arterial compliance adjusted for distending pressure; and plasma PTX3 concentrations. Results: Arterial compliance was significantly lower and the -stiffness index was significantly higher in obese men than in non-obese men. Plasma PTX3 concentration was markedly higher in obese than non-obese men. Conclusions: Obese men have lower arterial distensibility and higher circulating PTX3 levels than non-obese men; therefore, higher PTX3 levels and decreased arterial distensibility coexist in obese men. The high PTX3 concentrations in obese men may be involved in the mechanism underlying the obesity-induced decrease in arterial distensibility. J Atheroscler Thromb, 2010; 17:278-284.

show abstract

“…A recent trial showed that verapamil was effective in reducing blood pressure and heart rate in obese individuals [40]. Furthermore, verapamil is effective in reducing microalbuminuria, a common condition in obese patients [41].…”

Section: Calcium Channel Blockersmentioning

confidence: 99%

Management of hypertension in overweight and obese patients: A practical guide for clinicians

Dentali

Sharma

Douketis

2005

Current Science Inc

View full text Add to dashboard Cite

The association between obesity and cardiovascular disease is well established, and up to 60% of overweight or obese patients have hypertension. Dietary interventions associated with modest weight loss are effective in controlling blood pressure and in reducing use of antihypertensive drug therapy in overweight and obese patients. However, long-term maintenance of weight loss is achieved only in a small proportion of patients. Orlistat and sibutramine may help to achieve and maintain weight loss but may not be sufficient to control blood pressure in overweight and obese hypertensive patients. Consequently, antihypertensive drug therapy is often necessary in addition to weight loss interventions. Few studies have investigated different antihypertensive drugs, specifically in overweight and obese patients with hypertension. Based on studies involving obese and nonobese patients, first-line treatment options include a diuretic alone or an angiotensin-converting enzyme (ACE) inhibitor alone. If monotherapy is inadequate for blood pressure control, combination therapy with diuretic and ACE inhibitor and/or combining either of these drugs with a calcium channel blocker are reasonable treatment options. Additional studies to further clarify the management of these patients are warranted.

show abstract

Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension

Cited by 15 publications

References 16 publications

Ambulatory blood pressure monitoring in childhood and adult obesity

Ambulatory blood pressure monitoring in childhood and adult obesity

Is Pentraxin 3 Involved in Obesity-Induced Decrease in Arterial Distensibility?

Management of hypertension in overweight and obese patients: A practical guide for clinicians

Contact Info

Product

Resources

About